Kraemer 2012.

Study characteristics
Methods	A randomized study to assess the impact of pharmacist counseling of employer‐based health plan beneficiaries with diabetes: the EMPOWER study Patient RCT (NA clusters and NA providers), conducted in 5 Oregon employers and 2 Oregon‐based health insurance carriers collaborated with the OSU/Oregon Health and Science University College of Pharmacy (CoP). In USA. 2 arms: (control arm) (intervention arm)
Participants	Control arm N: 32 Intervention arm N: 37, NA, NA Diabetes type: 1 and 2 Mean age: NR ± NR % Male: NR Longest follow‐up: 12 months
Interventions	Control arm: 1) Patient education 2) Financial incentives Intervention arm: 1) Case management 2) Team change 3) Clinician education 4) Patient education 5) Promotion of self‐management 6) Financial incentives
Outcomes	1) Lipid‐lowering drugs 2) Antihypertensive drug 3) Glycated haemoglobin 4) Systolic blood pressure 5) Diastolic blood pressure 6) Low‐density lipoprotein
Funding source	Partial funding for this project was received from the Community Pharmacy Foundation, Sanofi‐Aventis and Lane County Pharmacists Association. The author(s) received no financial support for the authorship and/or publication of this article.
Notes	—
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described.
Allocation concealment (selection bias)	Unclear risk	Not described.
Patient's baseline characteristics (selection bias)	Unclear risk	Quote: "The proportion of females was somewhat higher in the control group", no P value.
Patient's baseline outcomes (selection bias)	Unclear risk	Not described in Table 1, P values not provided.
Incomplete outcome data (attrition bias)	High risk	Per‐protocol analysis, baseline based on those analysed. Withdrawal before study began (numbers were the same in each arm), but numbers and reasons for loss to follow‐up not reported.
Blinding of participants and personnel (performance bias) and of outcome assessors (detection bias)	Unclear risk	Primary: HbA1c; secondary; LDL, BP: objective laboratory methods not described. Blinding of outcome assessors not described. Blinding of participants was attempted.
Selective reporting (reporting bias)	Low risk	Matches protocol.
Risk of contamination (other bias)	Low risk	Information not available.
Other bias	Low risk	No evidence of other bias